Related references
Note: Only part of the references are listed.Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Peter A. Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer
I. F. Tannock et al.
ANNALS OF ONCOLOGY (2014)
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
M. Piccart et al.
ANNALS OF ONCOLOGY (2014)
Metastasis Dormancy in Estrogen Receptor-Positive Breast Cancer
Xiang H. -F. Zhang et al.
CLINICAL CANCER RESEARCH (2013)
Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer
P. K. Cheema et al.
CURRENT ONCOLOGY (2013)
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F. Cardoso et al.
ANNALS OF ONCOLOGY (2012)
Treatment of metastatic breast cancer: second line and beyond
H. Roche et al.
ANNALS OF ONCOLOGY (2011)
The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis
C. A. Harris et al.
ANNALS OF ONCOLOGY (2011)
The role of chemotherapy and targeted agents in patients with metastatic breast cancer
Stephen R. D. Johnston
EUROPEAN JOURNAL OF CANCER (2011)
Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies
Edward L. Korn et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Javier Cortes et al.
LANCET (2011)
In the End What Matters Most? A Review of Clinical Endpoints in Advanced Breast Cancer
Sunil Verma et al.
ONCOLOGIST (2011)
Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials
Everardo D. Saad et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Joseph A. Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined
E. D. Saad et al.
ANNALS OF ONCOLOGY (2009)
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
Kristine R. Broglio et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Metastatic breast cancer: The treatment challenge
Stephen E. Jones
CLINICAL BREAST CANCER (2008)
Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007
Nicholas Wilcken et al.
EUROPEAN JOURNAL OF CANCER (2008)
Her2-positive breast cancer: Herceptin and beyond
Windy Dean-Colomb et al.
EUROPEAN JOURNAL OF CANCER (2008)
Progression-free survival as a surrogate endpoint in advanced breast cancer
Rebecca A. Miksad et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2008)
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer
Tomasz Burzykowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer
Davide Mauri et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
The impact of new chemotherapeutic and agents on survival in a population-based of women with metastatic breast cancer hormone cohort
Stephen K. Chia et al.
CANCER (2007)
Correlation between time to progression and overall survival in patients with metastatic breast cancer
B. Sherrill et al.
VALUE IN HEALTH (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Goals of treatment for patients with metastatic breast cancer
I Smith
SEMINARS IN ONCOLOGY (2006)
Survival of metastatic breast carcinoma patients over a 20-year period - A retrospective analysis based on individual patient data from six consecutive studies
A Gennari et al.
CANCER (2005)
Breast cancer with synchronous metastases: Trends in survival during a 14-year period
F Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: A critical assessment based on recently reported phase III trials in colorectal and breast cancer
A Di Leo et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?
F Cardoso et al.
ANNALS OF ONCOLOGY (2002)
Share Paper
